Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CODOX-M/IVAC in HIV-Associated Burkitt's Lymphoma
NCT00392834Phase 2Completed
- Sponsor
- AIDS Malignancy Consortium
- Start
- Sep 2006
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Burkitt lymphoma (BL), sponsored by AIDS Malignancy Consortium. Started Sep 2006; status: completed.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT00392834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392834.